Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD

European Journal of Clinical Investigation

Volumn 43, Issue 6, 2013, Pages 562-569

  Boschetto, Piera ^a   Campo, Ilaria ^b   Stendardo, Mariarita ^a   Casimirri, Enrico ^a   Tinelli, Carmine ^b   Gorrini, Marina ^b   Ceconi, Claudio ^a   Fucili, Alessandro ^a   Potena, Alfredo ^a   Papi, Alberto ^a   Ballerin, Licia ^a   Fabbri, Leonardo ^c   Luisetti, Maurizio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Advanced glycation end products; Chronic heart failure; Chronic obstructive pulmonary disease; Inflammation; N terminal pro brain natriuretic peptide; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSINE DERIVATIVE; N CARBOXYMETHYLLYSINE; STEROID; UNCLASSIFIED DRUG;

AGED; ARTICLE; BODY MASS; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SMOKING;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART FAILURE; HUMANS; LYSINE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84877714204     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12079     Document Type: Article

References (31)

1. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004.
2. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002;105:816-22.
3. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
4. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109.
5. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716-27.
6. Wang LJ, Lu L, Zhang FR, Chen QJ, De Caterina R, Shen WF. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 2011;13:440-9.
7. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011;37:516-22.
8. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, et al. N (epsilon)- (carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996;35:8075-83.
9. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274:31740-9.
10. Sick E, Brehin S, André P, Coupin G, Landry Y, Takeda K, et al. Advanced glycation end products (AGEs) activate mast cells. Br J Pharmacol 2010;161:442-55.
11. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J 2007;28:2879-85.
12. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Moure-González M, Seoane-Blanco A, Varela-Román A, et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur J Heart Fail 2010;12:1092-100.
13. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Moure-González M, Seoane-Blanco A, Varela-Román A, et al. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am J Cardiol 2011;107:938-44.
14. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
15. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
16. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
17. Boschetto P, Fucili A, Stendardo M, Malagù M, Parrinello G, Casimirri E, et al. Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology 2013;18:125-30.
18. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
20. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580-6.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
23. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA, Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15:167-84.
24. Hartog JW, Voors AA, Bakker SJ, Smit AJ, Van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146-55.
25. Heidland A, Sebeková K, Frangiosa A, De Santo LS, Cirillo M, Rossi F, et al. Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. Heart 2004;90:1269-74.
26. Koyama Y, Takeishi Y, Niizeki T, Suzuki S, Kitahara T, Sasaki T, et al. Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 2008;14:133-9.
27. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012;39:721-9.
28. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011;12:37.
29. Chiurchiù V, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P, Baldini PM. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept 2008;148:26-32.
30. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86.
31. Inoue T, Kawai M, Nakane T, Nojiri A, Minai K, Komukai K, et al. Influence of low-grade inflammation on plasma B-type natriuretic peptide levels. Intern Med 2010;49:2659-68.